首页|行血液透析糖尿病肾病患者合并感染临床特点及肺炎克雷菌的耐药性分析

行血液透析糖尿病肾病患者合并感染临床特点及肺炎克雷菌的耐药性分析

扫码查看
目的 研究行血液透析的糖尿病肾病合并感染患者临床特点及肺炎克雷菌的耐药性,以期为临床合理使用抗生素提供科学依据.方法 选取268例接受血液透析治疗的糖尿病肾病合并感染患者为本次研究对象.收集患者不同感染部位的临床标本,进行病原菌鉴定及药敏试验,分析其对常用抗生素的耐药性.对比产超广谱-β内酰胺酶(ESBLs)肺炎克雷伯菌和非产ESBLs肺炎克雷伯菌的耐药性.结果 268例合并感染患者中,肺部感染142例(52.99%),消化道感染59例(22.01%),泌尿系统感染46例(17.16%),皮肤、软组织感染13例(4.85%),导管部位感染8例(2.99%).共检出病原菌268株,包括革兰阴性菌165株(61.57%),革兰阳性菌90株(33.58%),真菌13株(4.85%).在革兰阴性菌中,主要为肺炎克雷伯菌(25.37%,68/268)和大肠埃希菌(13.43%,36/268);在革兰阳性菌中,主要为金黄色葡萄球菌(13.06%,35/268)和肺炎链球菌(8.21%,22/268);真菌主要为白色假丝酵母菌(3.73%,10/268).68株肺炎克雷伯菌对氨苄西林、头孢唑林、头孢曲松、庆大霉素的耐药率高于50%,分别为80.88%、61.76%、50%、50%,对头孢吡肟、阿米卡星、亚胺培南、美罗培南、哌拉西林/他唑巴坦的耐药率低于30%,分别为29.41%、8.82%、10.29%、14.71%、17.65%.在68株肺炎克雷伯菌中,产ESBLs菌株检出率为35.29%.产ESBLs肺炎克雷伯菌对多种抗生素高度耐药,对阿米卡星等耐药率低于30%.非产ESBLs菌株对氨苄西林耐药率较高,对头孢曲松、阿米卡星等耐药率较低.两组菌株对氨苄西林、头孢唑林、头孢曲松、头孢他啶、头孢吡肟、庆大霉素、妥布霉素、左氧氟沙星、环丙沙星、美罗培南、氨曲南、氨苄西林/舒巴坦、哌拉西林/他唑巴坦的耐药率差异有统计学意义(P<0.05),对阿米卡星、亚胺培南的耐药率差异无统计学意义(P>0.05).结论 行血液透析糖尿病肾病患者合并感染患者主要为肺部感染,肺炎克雷伯菌是主要的病原菌之一,且产ESBLs菌株的耐药性问题较为严重.临床治疗时应重视对产ESBLs菌株的检测,并合理选择抗菌药物,以提高治疗效果,减少耐药菌株的产生和传播.
Study on the clinical characteristics of infection in diabetic nephropathy patients undergoing hemodialysis and the drug resistance of Klebsiella pneumoniae
Objective The clinical characteristics of diabetic nephropathy patients with infection undergoing hemodialysis and the drug resistance of Klebsiella pneumoniae were studied,in order to provide scientific basis for the rational use of antibiotics in clinic.Methods A total of 268 diabetic nephropathy patients with infection who received hemodialysis treatment in our hospital were selected as the research objects in this study.The clinical specimens from different infection sites of the patients were collected for pathogen identification and drug susceptibility testing,and their resistance to commonly used antibiotics was analyzed.The drug resistance of extended-spectrum beta-lactamase(ESBLs)-producing K.pneumoniae and non-ESBLs-producing K.pneumoniae was compared.Results Among the 268 patients with combined infections,there were 142 cases(52.99%)of pulmonary infection,59 cases(22.01%)of digestive tract infection,46 cases(17.16%)of urinary tract infection,13 cases(4.85%)of skin and soft tissue infection,and 8 cases(2.99%)of catheter site infection.A total of 268 pathogenic bacteria were detected,including 165 strains(61.57%)of Gram-negative bacteria,90 strains(33.58%)of Gram-positive bacteria,and 13 strains(4.85%)of fungi.Among Gram-negative bacteria,the main ones were K.pneumoniae(25.37%,68/268)and Escherichia coli(13.43%,36/268).Among Gram-positive bacteria,the main ones were Staphylococcus aureus(13.06%,35/268)and Streptococcus pneumoniae(8.21%,22/268).The main fungus was Candida albicans(3.73%,10/268).Among the 68 strains of K.pneumoniae,the drug resistance rates to ampicillin,cefazolin,ceftriaxone,and gentamicin were higher than 50%,which were 80.88%,61.76%,50%,and 50%respectively.The drug resistance rates to cefepime,amikacin,imipenem,meropenem,and piperacillin/tazobactam were lower than 30%,which were 29.41%,8.82%,10.29%,14.71%,and 17.65%respectively.Among the 68 strains of K.pneumoniae,the detection rate of ESBLs-producing strains was 35.29%.ESBLs-producing K.pneumoniae was highly resistant to multiple antibiotics,especially ampicillin and cefazolin.The resistance rate to drugs such as ceftriaxone exceeded 50%,but the resistance rate to a few drugs such as amikacin was less than 30%.Non-ESBLs-producing strains had a high resistance rate to ampicillin,but had a low resistance rate to many other drugs including ceftriaxone and amikacin.There were statistically significant differences in the comparison of drug resistance rates of the two groups of strains to ampicillin,cefazolin,ceftriaxone,ceftazidime,cefepime,gentamicin,tobramycin,levofloxacin,ciprofloxacin,meropenem,aztreonam,ampicillin/sulbactam,and piperacillin/tazobactam(P<0.05),while there was no statistically significant difference in the comparison of drug resistance rates to amikacin and imipenem(P>0.05).Conclusion In diabetic nephropathy patients undergoing hemodialysis and with combined infections,pulmonary infections were the main type.K.pneumoniae was one of the main pathogenic bacteria,and the drug resistance problem of ESBLs-producing strains was relatively serious.In clinical treatment,attention should be paid to the detection of ESBLs-producing strains,and antibacterial drugs should be rationally selected to improve the treatment effect and reduce the generation and spread of drug-resistant strains.

hemodialysisdiabetic nephropathyinfectionKlebsiella pneumoniaedrug resistance

李静、王宪娟、何昆

展开 >

邢台市中心医院,河北邢台 054000

血液透析 糖尿病肾病 感染 肺炎克雷伯菌 耐药性 ESBLs

2025

中国病原生物学杂志
中华预防医学会,山东省寄生虫病防治研究所

中国病原生物学杂志

北大核心
影响因子:1.219
ISSN:1673-5234
年,卷(期):2025.20(1)